Skip to main content
SpringerLink
Log in

Hyperkinetic Movement Disorders

  • Chapter
  • First Online:
Drug Abuse and Addiction in Medical Illness

  • 4491 Accesses

Abstract

The relationship between movement disorders and substance abuse can be examined from two approaches: first, assessment of the movements which occur secondary to substance abuse, and second, review of the movement disorders that might increase the propensity for substance abuse. This chapter will first address the myriad of hyperkinetic movements that can be seen in drug abusers, followed by a discussion of alcohol and two movement disorders (myoclonus-dystonia and essential tremor) in which patients may be at increased risk of alcohol abuse and dependence due to self-treatment of the disorders with alcohol. Hyperkinetic movement disorders include tremor, myoclonus, dystonia, chorea, athetosis, tics, akathisia, and stereotypies. Amphetamines have been associated with dystonia, chorea, tics, and tremors, and may exacerbate underlying movement disorders. In addition to worsening pre-existing movements, cocaine may cause tics, dystonia, chorea, myoclonus, and tremor. Movements associated with opioid use usually occur in the setting of medically ill patients, and include myoclonus and chorea. Alcohol, in contrast, may dampen some hyperkinetic movement disorders, and people with essential tremor and myoclonus-dystonia may use alcohol to self-treat symptoms. In some situations this has led to abuse which has been more damaging to the lives of the affected individuals than the underlying movement disorders.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Fahn S, Jankovic J. Principles and practice of movement disorders. Philadelphia: Churchill Livingstone/Elsevier; 2007.

    Google Scholar 

  2. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology. 1985;35:949–56.

    PubMed  CAS  Google Scholar 

  3. Bhidayasiri R, Truong DD. Chorea and related disorders. Postgrad Med J. 2004;80:527–34.

    PubMed  CAS  Google Scholar 

  4. Brust JCM. Neurological aspects of substance abuse. 2nd ed. Philadelphia, PA: Elsevier; 2004.

    Google Scholar 

  5. Kahlig KM, Galli A. Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol. 2003;479:153–8.

    PubMed  CAS  Google Scholar 

  6. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681–98.

    PubMed  CAS  Google Scholar 

  7. Fasano A, Barra A, Nicosia P, et al. Cocaine addiction: from habits to stereotypical-repetitive behaviors and punding. Drug Alcohol Depend. 2008;96:178–82.

    PubMed  CAS  Google Scholar 

  8. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir. 1972;75:203–12.

    PubMed  CAS  Google Scholar 

  9. Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med. 1988;6:131–3.

    PubMed  CAS  Google Scholar 

  10. Sperling LS, Horowitz JL. Methamphetamine-induced choreoathetosis and rhabdomyolysis. Ann Intern Med. 1994;121:986.

    PubMed  CAS  Google Scholar 

  11. Downes MA, Whyte IM. Amphetamine-induced movement disorder. Emerg Med Australas. 2005;17:277–80.

    PubMed  Google Scholar 

  12. Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. J Neurol Neurosurg Psychiatry. 1981;44:728–30.

    PubMed  CAS  Google Scholar 

  13. Shen YC. Amphetamine as a risk factor for aripiprazole-induced acute dystonia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1756–7.

    PubMed  CAS  Google Scholar 

  14. Brust JCM. Substance abuse and movement disorders. Mov Disord. 2010;25(13):2010–20.

    PubMed  Google Scholar 

  15. Nestler EJ. The neurobiology of cocaine addiction. Sci Pract Perspect. 2005;3:4–10.

    PubMed  Google Scholar 

  16. Factor SA, Sanchez-Ramos JR, Weiner WJ. Cocaine and Tourette’s syndrome. Ann Neurol. 1988;23:423–4.

    PubMed  CAS  Google Scholar 

  17. Cardoso FE, Jankovic J. Cocaine-related movement disorders. Mov Disord. 1993;8:175–8.

    PubMed  CAS  Google Scholar 

  18. Attig E, Amyot R, Botez T. Cocaine induced chronic tics. J Neurol Neurosurg Psychiatry. 1994;57:1143–4.

    PubMed  CAS  Google Scholar 

  19. Pascual-Leone A, Dhuna A. Cocaine-associated multifocal tics. Neurology. 1990;40:999–1000.

    PubMed  CAS  Google Scholar 

  20. Linazasoro G, Van Blercom N. Severe stuttering and motor tics responsive to cocaine. Parkinsonism Relat Disord. 2007;13:57–8.

    PubMed  CAS  Google Scholar 

  21. Catalano G, Catalano MC, Rodriguez R. Dystonia associated with crack cocaine use. South Med J. 1997;90:1050–2.

    PubMed  CAS  Google Scholar 

  22. Choy-Kwong M, Lipton RB. Dystonia related to cocaine withdrawal: a case report and pathogenic hypothesis. Neurology. 1989;39:996–7.

    PubMed  CAS  Google Scholar 

  23. Farrell PE, Diehl AK. Acute dystonic reaction to crack cocaine. Ann Emerg Med. 1991;20:322.

    PubMed  CAS  Google Scholar 

  24. Fines RE, Brady WJ, DeBehnke DJ. Cocaine-associated dystonic reaction. Am J Emerg Med. 1997;15:513–5.

    PubMed  CAS  Google Scholar 

  25. Merab J. Acute dystonic reaction to cocaine. Am J Med. 1988;84:564.

    PubMed  CAS  Google Scholar 

  26. Kumor K, Sherer M, Jaffe J. Haloperidol-induced dystonia in cocaine addicts. Lancet. 1986;2:1341–2.

    PubMed  CAS  Google Scholar 

  27. Maat A, Fouwels A, de Haan L. Cocaine is a major risk factor for antipsychotic induced akathisia, parkinsonism and dyskinesia. Psychopharmacol Bull. 2008;41:5–10.

    PubMed  Google Scholar 

  28. van Harten PN, van Trier JC, Horwitz EH, Matroos GE, Hoek HW. Cocaine as a risk factor for neuroleptic-induced acute dystonia. J Clin Psychiatry. 1998;59:128–30.

    PubMed  Google Scholar 

  29. Duggal HS. Cocaine use as a risk factor for ziprasidone-induced acute dystonia. Gen Hosp Psychiatry. 2007;29:278–9.

    PubMed  Google Scholar 

  30. Henderson JB, Labbate L, Worley M. A case of acute dystonia after single dose of aripiprazole in a man with cocaine dependence. Am J Addict. 2007;16:244.

    PubMed  Google Scholar 

  31. Daras M, Koppel BS, Atos-Radzion E. Cocaine-induced choreoathetoid movements (‘crack dancing’). Neurology. 1994;44:751–2.

    PubMed  CAS  Google Scholar 

  32. Habal R, Sauter D, Olowe O, Daras M. Cocaine and chorea. Am J Emerg Med. 1991;9:618–20.

    PubMed  CAS  Google Scholar 

  33. Kamath S, Bajaj N. Crack dancing in the United Kingdom: apropos a video case presentation. Mov Disord. 2007;22:1190–1.

    PubMed  Google Scholar 

  34. Weiner WJ, Rabinstein A, Levin B, Weiner C, Shulman LM. Cocaine-induced persistent dyskinesias. Neurology. 2001;56:964–5.

    PubMed  CAS  Google Scholar 

  35. Bartzokis G, Beckson M, Wirshing DA, Lu PH, Foster JA, Mintz J. Choreoathetoid movements in cocaine dependence. Biol Psychiatry. 1999;45:1630–5.

    PubMed  CAS  Google Scholar 

  36. Pierce RC, Kumaresan V. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev. 2006;30:215–38.

    PubMed  CAS  Google Scholar 

  37. Sethi KD. Drug-induced movement disorders. New York: Marcel Dekker; 2004.

    Google Scholar 

  38. Petzinger G, Mayer SA, Przedborski S. Fentanyl-induced dyskinesias. Mov Disord. 1995;10:679–80.

    PubMed  CAS  Google Scholar 

  39. Ferris DJ. Controlling myoclonus after high-dosage morphine infusions. Am J Health Syst Pharm. 1999;56:1009–10.

    PubMed  CAS  Google Scholar 

  40. Potter JM, Reid DB, Shaw RJ, Hackett P, Hickman PE. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ. 1989;299:150–3.

    PubMed  CAS  Google Scholar 

  41. Gattera JA, Charles BG, Williams GM, Cavenagh JD, Smithurst BA, Luchjenbroers J. A retrospective study of risk factors of akathisia in terminally ill patients. J Pain Symptom Manage. 1994;9:454–61.

    PubMed  CAS  Google Scholar 

  42. Mercadante S. Opioids and akathisia. J Pain Symptom Manage. 1995;10:415.

    PubMed  CAS  Google Scholar 

  43. De Conno F, Caraceni A, Martini C, Spoldi E, Salvetti M, Ventafridda V. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain. 1991;47:337–9.

    PubMed  Google Scholar 

  44. Mercadante S. Pathophysiology and treatment of opioid-related myoclonus in cancer patients. Pain. 1998;74:5–9.

    PubMed  CAS  Google Scholar 

  45. Latta KS, Ginsberg B, Barkin RL. Meperidine: a critical review. Am J Ther. 2002;9:53–68.

    PubMed  Google Scholar 

  46. Ito S, Liao S. Myoclonus associated with high-dose parenteral methadone. J Palliat Med. 2008;11:838–41.

    PubMed  Google Scholar 

  47. Mercadante S. Dantrolene treatment of opioid-induced myoclonus. Anesth Analg. 1995;81:1307–8.

    PubMed  CAS  Google Scholar 

  48. Sarhill N, Davis MP, Walsh D, Nouneh C. Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care. 2001;18:51–3.

    PubMed  CAS  Google Scholar 

  49. Bonnet U, Banger M, Wolstein J, Gastpar M. Choreoathetoid movements associated with rapid adjustment to methadone. Pharmacopsychiatry. 1998;31:143–5.

    PubMed  CAS  Google Scholar 

  50. Clark JD, Elliott J. A case of a methadone-induced movement disorder. Clin J Pain. 2001;17:375–7.

    PubMed  CAS  Google Scholar 

  51. Wasserman S, Yahr MD. Choreic movements induced by the use of methadone. Arch Neurol. 1980;37:727–8.

    PubMed  CAS  Google Scholar 

  52. Hall AP, Henry JA. Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth. 2006;96:678–85.

    PubMed  CAS  Google Scholar 

  53. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol. 2005;5:79–86.

    PubMed  CAS  Google Scholar 

  54. Downing J. The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs. 1986;18:335–40.

    PubMed  CAS  Google Scholar 

  55. Peroutka SJ, Newman H, Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology. 1988;1:273–7.

    PubMed  CAS  Google Scholar 

  56. Vollenweider FX, Gamma A, Liechti M, Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychop­harmacology. 1998;19:241–51.

    PubMed  CAS  Google Scholar 

  57. Cosentino C. Ecstasy and acute dystonia. Mov Disord. 2004;19:1386–7; author reply 1387.

    Google Scholar 

  58. Priori A, Bertolasi L, Berardelli A, Manfredi M. Acute dystonic reaction to ecstasy. Mov Disord. 1995;10:353.

    PubMed  CAS  Google Scholar 

  59. Parrott AC, Buchanan T, Scholey AB, Heffernan T, Ling J, Rodgers J. Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol. 2002;17:309–12.

    PubMed  CAS  Google Scholar 

  60. Parrott AC, Lasky J. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl). 1998;139:261–8.

    CAS  Google Scholar 

  61. Cole JC, Sumnall HR. Altered states: the clinical effects of Ecstasy. Pharmacol Ther. 2003;98:35–58.

    PubMed  CAS  Google Scholar 

  62. Kalant H. The pharmacology and toxicology of “ecstasy” (MDMA) and related drugs. CMAJ. 2001;165:917–28.

    PubMed  CAS  Google Scholar 

  63. Iravani MM, Jackson MJ, Kuoppamaki M, Smith LA, Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-­phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci. 2003;23:9107–15.

    PubMed  CAS  Google Scholar 

  64. Mintzer S, Hickenbottom S, Gilman S. Parkinsonism after taking ecstasy. N Engl J Med. 1999;340:1443.

    PubMed  CAS  Google Scholar 

  65. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“ecstasy”). Science. 2002;297:2260–3.

    PubMed  CAS  Google Scholar 

  66. Ricaurte GA, Yuan J, Hatzidimitriou G, Cord BJ, McCann UD. Retraction. Science. 2003;301:1479.

    PubMed  CAS  Google Scholar 

  67. Lozsadi DA, Forster A, Fletcher NA. Cannabis-induced propriospinal myoclonus. Mov Disord. 2004;19:708–9.

    PubMed  Google Scholar 

  68. Chatterjee A, Almahrezi A, Ware M, Fitzcharles MA. A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. J Pain Symptom Manage. 2002;24:4–6.

    PubMed  Google Scholar 

  69. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol Biochem Behav. 1991;40:701–8.

    PubMed  CAS  Google Scholar 

  70. Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord. 2002;17:145–9.

    PubMed  Google Scholar 

  71. Muller-Vahl KR. Cannabinoids reduce symptoms of Tourette’s syndrome. Expert Opin Pharmacother. 2003;4:1717–25.

    PubMed  Google Scholar 

  72. Muller-Vahl KR, Schneider U, Prevedel H, et al. Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry. 2003;64:459–65.

    PubMed  Google Scholar 

  73. Uribe Roca MC, Micheli F, Viotti R. Cannabis sativa and dystonia secondary to Wilson’s disease. Mov Disord. 2005;20:113–5.

    PubMed  Google Scholar 

  74. Huang MC, Lin HY, Chen CH. Dependence on zolpidem. Psychiatry Clin Neurosci. 2007;61:207–8.

    PubMed  Google Scholar 

  75. Lightman SL. Phenobarbital dyskinesia. Postgrad Med J. 1978;54:114–5.

    PubMed  CAS  Google Scholar 

  76. McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA. Acute phencyclidine intoxication: clinical patterns, complications, and treatment. Ann Emerg Med. 1981;10:290–7.

    PubMed  CAS  Google Scholar 

  77. Shiigi Y, Casey DE. Behavioral effects of ketamine, an NMDA glutamatergic antagonist, in non-human primates. Psychophar­macology (Berl). 1999;146:67–72.

    CAS  Google Scholar 

  78. Finch CK, Lobo BL. Acute inhalant-induced neurotoxicity with delayed recovery. Ann Pharmacother. 2005;39:169–72.

    PubMed  Google Scholar 

  79. Bartolucci G, Pellettier JR. Glue sniffing and movement disorder. J Neurol Neurosurg Psychiatry. 1984;47:1259.

    PubMed  CAS  Google Scholar 

  80. Neiman J, Lang AE, Fornazzari L, Carlen PL. Movement disorders in alcoholism: a review. Neurology. 1990;40:741–6.

    PubMed  CAS  Google Scholar 

  81. Carlen PL, Lee MA, Jacob M, Livshits O. Parkinsonism provoked by alcoholism. Ann Neurol. 1981;9:84–6.

    PubMed  CAS  Google Scholar 

  82. Lang AE, Marsden CD, Obeso JA, Parkes JD. Alcohol and Parkinson disease. Ann Neurol. 1982;12:254–6.

    PubMed  CAS  Google Scholar 

  83. Luijckx GJ, Nieuwhof C, Troost J, Weber WE. Parkinsonism in alcohol withdrawal: case report and review of the literature. Clin Neurol Neurosurg. 1995;97:336–9.

    PubMed  CAS  Google Scholar 

  84. Neiman J, Borg S, Wahlund LO. Parkinsonism and dyskinesias during ethanol withdrawal. Br J Addict. 1988;83:437–9.

    PubMed  CAS  Google Scholar 

  85. Shandling M, Carlen PL, Lang AE. Parkinsonism in alcohol withdrawal: a follow-up study. Mov Disord. 1990;5:36–9.

    PubMed  CAS  Google Scholar 

  86. Mullin PJ, Kershaw PW, Bolt JM. Choreoathetotic movement disorder in alcoholism. Br Med J. 1970;4:278–81.

    PubMed  CAS  Google Scholar 

  87. Balldin J, Alling C, Gottfries CG, Lindstedt G, Langstrom G. Changes in dopamine receptor sensitivity in humans after heavy alcohol intake. Psychopharmacology (Berl). 1985;86:142–6.

    CAS  Google Scholar 

  88. Louis ED, Barnes LF, Ford B, Pullman SL, Yu Q. Ethnic differences in essential tremor. Arch Neurol. 2000;57:723–7.

    PubMed  CAS  Google Scholar 

  89. Klebe S, Stolze H, Grensing K, Volkmann J, Wenzelburger R, Deuschl G. Influence of alcohol on gait in patients with essential tremor. Neurology. 2005;65:96–101.

    PubMed  CAS  Google Scholar 

  90. Louis ED. Environmental epidemiology of essential tremor. Neuroepidemiology. 2008;31:139–49.

    PubMed  Google Scholar 

  91. Lambert D, Waters CH. Essential tremor. Curr Treat Options Neurol. 1999;1:6–13.

    PubMed  Google Scholar 

  92. Louis ED, Vonsattel JP. The emerging neuropathology of essential tremor. Mov Disord. 2008;23:174–82.

    PubMed  Google Scholar 

  93. Tan EK, Schapira AH. Hunting for genes in essential tremor. Eur J Neurol. 2008;15:889–90.

    PubMed  CAS  Google Scholar 

  94. Deuschl G, Elble RJ. The pathophysiology of essential tremor. Neurology. 2000;54:S14–20.

    PubMed  CAS  Google Scholar 

  95. Jenkins IH, Bain PG, Colebatch JG, et al. A positron emission tomography study of essential tremor: evidence for overactivity of cerebellar connections. Ann Neurol. 1993;34:82–90.

    PubMed  CAS  Google Scholar 

  96. Louis ED, Shungu DC, Chan S, Mao X, Jurewicz EC, Watner D. Metabolic abnormality in the cerebellum in patients with essential tremor: a proton magnetic resonance spectroscopic imaging study. Neurosci Lett. 2002;333:17–20.

    PubMed  CAS  Google Scholar 

  97. Pagan FL, Butman JA, Dambrosia JM, Hallett M. Evaluation of essential tremor with multi-voxel magnetic resonance spectroscopy. Neurology. 2003;60:1344–7.

    PubMed  Google Scholar 

  98. Shin DH, Han BS, Kim HS, Lee PH. Diffusion tensor imaging in patients with essential tremor. Am J Neuroradiol. 2008;29:151–3.

    PubMed  CAS  Google Scholar 

  99. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2005;64:2008–20.

    PubMed  CAS  Google Scholar 

  100. Critchley M. Observations on essential (heredofamial) tremor. Brain. 1949;72:113–39.

    PubMed  CAS  Google Scholar 

  101. Koller WC. A new drug for treatment of essential tremor? Time will tell. Mayo Clin Proc. 1991;66:1085–7.

    PubMed  CAS  Google Scholar 

  102. Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary essential tremor. Brain. 1994;117(Pt 4):805–24.

    PubMed  Google Scholar 

  103. Growdon JH, Shahani BT, Young RR. The effect of alcohol on essential tremor. Neurology. 1975;25:259–62.

    PubMed  CAS  Google Scholar 

  104. Boecker H, Weindl A, Leenders K, et al. Secondary parkinsonism due to focal substantia nigra lesions: a PET study with [18F]FDG and [18F]fluorodopa. Acta Neurol Scand. 1996;93:387–92.

    PubMed  CAS  Google Scholar 

  105. Kralic JE, Criswell HE, Osterman JL, et al. Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. J Clin Invest. 2005;115:774–9.

    PubMed  CAS  Google Scholar 

  106. Loewenstein Y. A possible role of olivary gap-junctions in the generation of physiological and pathological tremors. Mol Psychiatry. 2002;7:129–31.

    PubMed  CAS  Google Scholar 

  107. Manto M, Laute MA. A possible mechanism for the beneficial effect of ethanol in essential tremor. Eur J Neurol. 2008;15:697–705.

    PubMed  CAS  Google Scholar 

  108. Nasrallah HA, Schroeder D, Petty F. Alcoholism secondary to essential tremor. J Clin Psychiatry. 1982;43:163–4.

    PubMed  CAS  Google Scholar 

  109. Schroeder D, Nasrallah HA. High alcoholism rate in patients with essential tremor. Am J Psychiatry. 1982;139:1471–3.

    PubMed  CAS  Google Scholar 

  110. Koller WC. Alcoholism in essential tremor. Neurology. 1983;33:1074–6.

    PubMed  CAS  Google Scholar 

  111. Rautakorpi I, Marttila RJ, Rinne UK. Alcohol consumption of patients with essential tremor. Acta Neurol Scand. 1983;68:177–9.

    PubMed  CAS  Google Scholar 

  112. Hess CW, Saunders-Pullman R. Movement disorders and alcohol misuse. Addict Biol. 2006;11:117–25.

    PubMed  Google Scholar 

  113. Saunders-Pullman R, Ozelius L, Bressman SB. Inherited myoclonus-dystonia. Adv Neurol. 2002;89:185–91.

    PubMed  Google Scholar 

  114. Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet. 2001;29:66–9.

    PubMed  CAS  Google Scholar 

  115. Chan P, Gonzalez-Maeso J, Ruf F, Bishop DF, Hof PR, Sealfon SC. Epsilon-sarcoglycan immunoreactivity and mRNA expression in mouse brain. J Comp Neurol. 2005;482:50–73.

    PubMed  CAS  Google Scholar 

  116. Xiao J, LeDoux MS. Cloning, developmental regulation and neural localization of rat epsilon-sarcoglycan. Brain Res Mol Brain Res. 2003;119:132–43.

    PubMed  CAS  Google Scholar 

  117. Asmus F, Zimprich A, Naumann M, et al. Inherited myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families. Ann Neurol. 2001;49:121–4.

    PubMed  CAS  Google Scholar 

  118. Doheny DO, Brin MF, Morrison CE, et al. Phenotypic features of myoclonus-dystonia in three kindreds. Neurology. 2002;59:1187–96.

    PubMed  CAS  Google Scholar 

  119. Hedrich K, Meyer EM, Schule B, et al. Myoclonus-dystonia: detection of novel, recurrent, and de novo SGCE mutations. Neurology. 2004;62:1229–31.

    PubMed  CAS  Google Scholar 

  120. Hess CW, Raymond D, Aguiar Pde C, et al. Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers. Neurology. 2007;68:522–4.

    PubMed  CAS  Google Scholar 

  121. Kyllerman M, Forsgren L, Sanner G, Holmgren G, Wahlstrom J, Drugge U. Alcohol-responsive myoclonic dystonia in a large family: dominant inheritance and phenotypic variation. Mov Disord. 1990;5:270–9.

    PubMed  CAS  Google Scholar 

  122. Marechal L, Raux G, Dumanchin C, et al. Severe myoclonus-dystonia syndrome associated with a novel epsilon-sarcoglycan gene truncating mutation. Am J Med Genet B Neuropsychiatr Genet. 2003;119B:114–7.

    PubMed  Google Scholar 

  123. Nygaard TG, Raymond D, Chen C, et al. Localization of a gene for myoclonus-dystonia to chromosome 7q21-q31. Ann Neurol. 1999;46:794–8.

    PubMed  CAS  Google Scholar 

  124. Mahloudji M, Pikielny RT. Hereditary essential myoclonus. Brain. 1967;90:669–74.

    PubMed  CAS  Google Scholar 

  125. Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord. 1996;11:119–24.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA

    Christopher Hess M.D.

  2. Department of Neurology, Beth Israel Medical Center, New York, NY, 10003, USA

    Rachel Saunders-Pullman M.D., M.P.H.

  3. Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA

    Rachel Saunders-Pullman M.D., M.P.H.

Authors
  1. Christopher Hess M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachel Saunders-Pullman M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher Hess M.D. .

Editor information

Editors and Affiliations

  1. Inst. Pharmaceutical Sciences, Department of Psychopharmacology, Utrecht University, Universiteitsweg 99, Utrecht, 3584CG, Netherlands

    Joris C. Verster

  2. Dept. Psychiatry, Medical University of South Carolina, President St. 67, Charleston, 29425, South Carolina, USA

    Kathleen Brady

  3. School of Medicine, Div. Alcoholism & Drug Abuse, New York University, First Ave. 550, New York, 10016, New York, USA

    Marc Galanter

  4. Institute of Psychiatry, King's College London, National Addiction Centre, Windsor Walk 4, London, SE5 8AF, United Kingdom

    Patricia Conrod

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Hess, C., Saunders-Pullman, R. (2012). Hyperkinetic Movement Disorders. In: Verster, J., Brady, K., Galanter, M., Conrod, P. (eds) Drug Abuse and Addiction in Medical Illness. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3375-0_34

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3375-0_34

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3374-3

  • Online ISBN: 978-1-4614-3375-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation